ABBOTT, SCHOELLHORN ATTORNEYS WILL MEET JUNE 14
Executive Summary
ABBOTT, SCHOELLHORN ATTORNEYS WILL MEET JUNE 14 to argue an Abbott motion to dismiss the complaint brought by ex-chairman Schoellhorn. The former Abbott exec filed a "wrongful firing" suit on March 9 after the company removed him from his position as chairman of the board. Abbott filed the motion to dismiss on April 6. "This complaint is a cry of wounded vanity, not a cognizable cause of action in Illinois," Abbott charged in the dismissal motion, filed with Judge Anthony Scotillo at the Cook County Circuit Court in Chicago. The motion challenges all four counts in the complaint. For example, the motion says Schoellhorn seeks reinstatement as chairman on the grounds that a Dec. 8 resolution reducing his powers was "improper." Abbott argued that because the count does not challenge the March 9 board action that actually terminated him, the count should be dismissed. The remaining three counts involve an alleged agreement that Abbott would employ Schoellhorn until he reaches retirement age at 65. Schoellhorn is now 61. The dismissal motion argues that: "First, the only 'contract' alleged in Count II is a purported oral agreement to employ Schoellhorn for four more years, until he is 65. But the complaint fails to allege a single term of the alleged agreement other than its four year duration." Moreover, Abbott argues that "this fragmentary promise -- even if it had been made -- would not rise to the level of a contract." Abbott plans to argue that under the Illinois Statute of Frauds, an oral contract is only enforceable if it is "performable" within one year. Just prior to the April 4 hearing, Abbott filed a motion charging Schoellhorn with six counts of misappropriation of funds, fraud and abuse of power. At the hearing, the court partially dissolved a temporary restraining order, allowing Abbott to officially terminate Schoellhorn without ruling on the issue of cause ("The Pink Sheet" April 9, T&G-6). If Abbott is eventually successful in arguing that the company fired Schoellhorn "for cause," the former executive will be forced to forfeit 51,000 shares of restricted stock, now frozen pending further court actions.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth